Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia

Retina

Volumn 31, Issue 4, 2011, Pages 669-672

  Inman, Zachary Daniel ^a   Anderson, Nicholas Gray ^a,b  

^a Southeastern Retina Associates   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LIDOCAINE; PEGAPTANIB; RANIBIZUMAB;

ARTICLE; ENDOPHTHALMITIS; FOLLOW UP; GEL; HUMAN; INCIDENCE; INFECTION RATE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; TOPICAL ANESTHESIA;

ANESTHESIA, LOCAL; ANESTHETICS, LOCAL; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; LIDOCAINE; RETROSPECTIVE STUDIES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79955050933     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181ef463d     Document Type: Article

References (19)

1. Assia EI, Pras E, Yehezkel M, Rotenstreich Y, Jager-Roshu S. Topical anesthesia using lidocaine gel for cataract surgery. J Cataract Refract Surg 1999;25:635-639. (Pubitemid 29222591)
2. Kozak I, Cheng L, Freeman WR. Lidocaine gel anesthesia for intravitreal drug administration. Retina 2005;25:994-998. (Pubitemid 44735096)
3. Friedman SM, Margo CE. Topical gel vs subconjunctival lidocaine for intravitreous injection: a randomized clinical trial. Am J Ophthalmol 2006;142:887-888. (Pubitemid 44584156)
4. Miller JJ, Scott IU, Flynn HW, Smiddy WE, Newton J,Miller D. Acute-onset endophthalmitis after cataract surgery (2000- 2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139:983-987.
5. Boden JH, Myers ML, Lee T, Bushley M, Torres MF. Effect of lidocaine gel on povidone-iodine antisepsis and microbial survival. J Cataract Refract Surg 2008;34:1773-1775.
6. Holz ER. Reducing endophthalmitis risk factors: where we stand. Am J Ophthalmol 2005;139:1097-1098. (Pubitemid 40813325)
7. Scott IU, Flynn HW Jr. Intravitreal injections: guidelines to minimize the risk of endophthalmitis. In: Joussen AM, Gardner TW, Kirchhof B, Ryan SJ, eds. Retinal Vascular Disease. Danvers, MA: Springer; 2007:283-288.
8. Diabetic Retinopathy Clinical Research Network. Laser- Ranibizumab-Triamcinolone for Diabetic Macular Edema. Study Procedures. Site Procedures Manual. Version 4.0. July 1, 2008. Page 3.
9. Comparison of Age-Related Macular Degeneration Treatment Trials. Procedure Manual. November 2007. Section I (d). Pages 4-8.
10. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for Neovascular Age-Related Macular Degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
11. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112: 1747-1757.
12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
13. Heier JS, Antosyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633-642.
14. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
15. Mason JO, Withe MF, Feist RM, et al. Incidence of acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567. (Pubitemid 351589565)
16. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-1399.
17. Klein KS,WalshMK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections [letter]. Ophthalmology 2009; 116:1225.
18. Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009;23: 2187-2193.
19. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-S19. (Pubitemid 39391785)